Business context and reporting period
Entity mismatch: The filing provided is Salarius Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended June 30, 2023, not a filing identified as Decoy Therapeutics Inc. The summary below covers Salarius.
Salarius is a clinical-stage biotechnology company developing SP-3164, a targeted protein degrader, and seclidemstat (SP-2577), a targeted protein inhibitor. It has no products approved for sale and has not generated product-sale revenue.
Financial results and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Research and development expense | $2.35 million | $2.92 million | $6.08 million | $7.36 million |
| General and administrative expense | $1.62 million | $1.84 million | $3.31 million | $3.51 million |
| Net loss | $3.88 million | $4.72 million | $9.22 million | $10.83 million |
| Basic and diluted loss per share | $1.43 | $2.20 | $3.45 | $5.42 |
| Operating cash used | Not separately provided for the quarter | $7.59 million | $7.14 million |
At June 30, 2023, cash and cash equivalents were $11.54 million, working capital was $8.3 million, total assets were $12.06 million, and total liabilities were $3.64 million. The filing reports no borrowings on the balance sheet. Six-month financing cash inflow was $7.02 million, mainly from equity issuance; cash declined by $0.56 million over the period. No operating margin is meaningful given the company’s operating losses and lack of product sales.
Changes versus the prior comparable period
Q2 net loss narrowed by $0.84 million year over year; six-month net loss narrowed by $1.61 million. Lower SP-2577 spending drove the R&D decline, partly offset by higher SP-3164 spending. Six-month operating cash use increased by about $0.45 million, which management attributed primarily to a decrease in accounts payable. The 2022 comparison included $1.99 million of acquired in-process R&D expense and $1.50 million of related investing cash outflow; neither recurred in the first half of 2023.
In May 2023, the company raised approximately $6.0 million gross in a private placement and also sold shares through its at-the-market program. Common shares outstanding increased from 2.26 million at December 31, 2022 to 3.35 million at June 30, 2023. The filing also reports substantial outstanding warrants and pre-funded warrants, creating potential dilution.
Outlook, risks and unusual items
- Liquidity and going concern: Management states that existing funding is insufficient to support current and planned clinical programs for more than 12 months from the filing date. The company reported substantial doubt about its ability to continue as a going concern. It expected June 30 cash, together with restructuring, to fund current and restructured operations through Q4 2023.
- Strategic review and cost reductions: After quarter-end, Salarius retained Canaccord Genuity to review alternatives including a merger, acquisition, asset sale, licensing or other transaction. The process has no set timetable and may not produce a transaction; an orderly wind-down remains a possible outcome. A plan approved August 5 calls for workforce reductions exceeding 50%, with execution expected to be substantially complete by Q4 2023. Estimated severance and other employee-related costs are approximately $1.2 million, primarily in Q3 and Q4.
- Development plans: The company expects R&D spending to decline in the remainder of 2023 and into 2024 as it limits development and evaluates strategic alternatives. The FDA cleared the SP-3164 IND for clinical investigations in non-Hodgkin lymphoma on July 11, 2023. Seclidemstat was in a Phase 1/2 trial for relapsed/refractory Ewing sarcoma in combination with chemotherapy.
- Risks and contingencies: Failure to secure financing or complete a strategic transaction could require further cuts, delayed or discontinued development, or liquidation. The company warns that its warrants may complicate transactions and financing and could reduce common shareholders’ share of transaction proceeds. Nasdaq listing compliance is also at risk; the filing notes an August 7 closing share price of $0.86, below the exchange’s minimum trading price requirement.
- Other: Salarius had approximately $0.1 million in CPRIT grant receivables at June 30, 2023; its grant extension ran through November 30, 2023. The filing reports no material legal proceedings.
Important facts for investors to verify
- Confirm the issuer: this source is Salarius Pharmaceuticals, Inc., not Decoy Therapeutics Inc.
- Review subsequent filings for cash runway, restructuring charges, workforce reductions and any additional financing.
- Track the strategic-alternatives process and the possibility of a transaction, wind-down or liquidation.
- Assess the full potential dilution and transaction impact of outstanding warrants and pre-funded warrants.
- Check Nasdaq listing compliance and clinical-program status, including any updates to the SP-3164 and seclidemstat programs.